Seer Urges Stockholders to Vote “FOR” Seer’s Highly Qualified Director Nominees on the BLUE Proxy Card TODAY
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Details
News Market Reaction – SEER
On Jul 20, the day this news came out, SEER closed 5.99% below the previous close. Argus tracked a trough of -2.9% from its starting point during tracking. Our momentum scanner recorded 7 alerts for this stock that day.
Data tracked by StockTitan Argus for the Jul 20 session.
Key Figures
- Annual meeting date
- July 28, 2026
- 2026 Annual Meeting of Stockholders
- Meeting time
- 1:30 p.m. Pacific Time
- 2026 Annual Meeting of Stockholders
- Voting record date
- May 29, 2026
- Stockholders entitled to vote
- Director nominees
- 7 nominees
- Board-recommended slate on the BLUE proxy card
- Board ownership
- 17% of outstanding shares
- Collective ownership by Seer’s Board
Historical Context
-
Board issued a shareholder letter addressing the ongoing proxy contest
-
Radoff-JEC Group issued a letter disputing Seer’s account of events
-
Seer highlighted the strength and experience of its director nominees
-
Radoff-JEC Group responded to the CEO’s proposal to acquire Seer
-
Seer presented commercial momentum and long-term value creation potential
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
proteomics medical
proxy card regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
2026 Annual Meeting of Stockholders To Be Held July 28, 2026
Seer’s Board of Directors is Highly Engaged, Independent and Purpose-Built to Oversee Strategic
Execution at This Critical Time
Radoff-JEC Group’s Nominees Lack Qualifications, Expertise and Independence Necessary to Add Value to Board
REDWOOD CITY, Calif., July 20, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”) today issued a letter to stockholders reminding them to vote their shares ahead of the Company’s upcoming 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to be held on July 28, 2026 at 1:30 p.m. Pacific Time. Stockholders as of May 29, 2026 are entitled to vote at the Annual Meeting.
The Board recommends that stockholders vote “FOR” ONLY the election of Seer’s seven highly qualified nominees on the BLUE proxy card: Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D.
The Board strongly urges stockholders to vote TODAY to ensure their vote is timely submitted.
The full text of the letter follows:
Dear Fellow Seer Stockholders,
Seer’s 2026 Annual Meeting of Stockholders is scheduled to be held on July 28, 2026. You have an important decision to make, and time is running short. Seer’s Board strongly urges you to vote “FOR” ONLY Seer’s highly qualified director nominees on the BLUE proxy card TODAY to protect the value of your investment in Seer.
Seer is executing a clear long-term growth strategy, guided by our commitments to operational discipline, product innovation and shareholder value creation. We are pioneering a new market in deep, unbiased proteomics, growing scientific validation of our technology, advancing population-scale studies, maintaining prudent capital allocation, and building toward durable commercial adoption. Through this work, Seer has established itself as the leader in the category that we created. As our commercial opportunity continues to accelerate, we are well-positioned to realize the full potential of our platform.
Seer’s Board is highly engaged, independent and purpose-built to guide a category-creating life sciences tools company. Our seven director nominees – Omid Farokhzad, M.D.; Meeta Gulyani; Robert Langer, Sc.D.; Terrance McGuire; Dipchand (Deep) Nishar; Isaac Ro; and Nicolas Roelofs, Ph.D. – are seasoned industry experts well-qualified to oversee Seer’s continued strategic execution at this critical time. The Board collectively owns
Bradley Radoff and Michael Torok are seeking to disrupt Seer’s strong momentum through a self-interested campaign focused on forcing an early sale of Seer. To advance this short-term agenda, Radoff and Torok are asking you to support director nominees who lack the qualifications, expertise and independence necessary to add value to our Board. The election of these nominees would mean replacing deeply qualified, highly committed directors – Dr. Farokhzad, Mr. McGuire and Mr. Nishar – with candidates who bring no proteomics experience, no life sciences tools experience and no platform operating experience. That is a risk you should not take.
Do not let Radoff and Torok take control of Seer’s future. Our Board is committed to maximizing long-term value for all stockholders. Radoff and Torok are focused on depriving stockholders of the opportunity to realize the full value of the platform that you have funded.
The choice is clear: vote “FOR” ONLY Seer’s director nominees on the BLUE proxy card TODAY.
Thank you for your continued support of Seer.
Sincerely,
The Seer Board of Directors
If you have any questions or require any assistance with voting your shares,
please call:
Innisfree M&A Incorporated
Stockholders may call toll free: (877) 456-3524
Advisors
Perella Weinberg Partners LP is serving as financial advisor to Seer and Wilson Sonsini Goodrich & Rosati, Professional Corporation is serving as legal counsel.
About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with a scale, speed, precision and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables and advanced analytical software to overcome the limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio.
For more information, please email us at pr@seer.bio.
Forward-Looking Statements
This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s plans, strategies, expectations, strategic opportunities, stockholder value initiatives and expectations, business objectives, commercial opportunity, profitability expectations, research and development initiatives, and prospects. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission and other documents that Seer subsequently files with the Securities and Exchange Commission from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Media Contact:
Patrick Schmidt
pr@seer.bio
Joele Frank, Wilkinson Brimmer Katcher
Eric Brielmann / Joseph Sala
(212) 355-4449
Investor Contact:
Marissa Bych
investor@seer.bio
___________________________________________
1 Total shares outstanding as of May 11, 2026
